UNITED THERAPEUTICS COMPLETES EUROPEAN MUTUAL RECOGNITION FOR REMODULIN(R)

United Therapeutics Corporation (Nasdaq: UTHR -- News) announced today that the European Union Mutual Recognition Procedure (MRP) has been completed for Remodulin (treprostinil sodium) Injection for the subcutaneous treatment of NYHA Class III Primary Pulmonary Hypertension patients. "Our pursuit of the European approvals and resubmissions demonstrates our commitment to making Remodulin available as widely as practical," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and CEO.

Yahoo News (http://biz.yahoo.com/prnews/050810/dcw035.html?.v=21)